WallStSmart

Amgen Inc (AMGN)vsIntuitive Surgical Inc (ISRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amgen Inc generates 265% more annual revenue ($36.75B vs $10.06B). ISRG leads profitability with a 28.4% profit margin vs 21.0%. AMGN appears more attractively valued with a PEG of 2.33. AMGN earns a higher WallStSmart Score of 70/100 (B-).

AMGN

Strong Buy

70

out of 100

Grade: B-

Growth: 8.0Profit: 8.5Value: 10.0Quality: 5.0
Piotroski: 4/9

ISRG

Buy

62

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 4.7Quality: 7.8
Piotroski: 4/9Altman Z: 6.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMGNUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$665.50

Current Price

$353.93

$311.57 discount

UndervaluedFair: $665.50Overvalued
ISRGSignificantly Overvalued (-78.8%)

Margin of Safety

-78.8%

Fair Value

$262.88

Current Price

$469.98

$207.10 premium

UndervaluedFair: $262.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMGN5 strengths · Avg: 9.6/10
Return on EquityProfitability
106.1%10/10

Every $100 of equity generates 106 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

EPS GrowthGrowth
112.1%10/10

Earnings expanding 112.1% YoY

Market CapQuality
$187.83B9/10

Large-cap with strong market position

Profit MarginProfitability
21.0%9/10

Keeps 21 of every $100 in revenue as profit

ISRG5 strengths · Avg: 9.2/10
Operating MarginProfitability
30.2%10/10

Strong operational efficiency at 30.2%

Altman Z-ScoreHealth
6.1810/10

Safe zone — low bankruptcy risk

Market CapQuality
$167.61B9/10

Large-cap with strong market position

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

Areas to Watch

AMGN2 concerns · Avg: 3.0/10
PEG RatioValuation
2.334/10

Expensive relative to growth rate

Price/BookValuation
22.0x2/10

Trading at 22.0x book value

ISRG3 concerns · Avg: 3.3/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

Price/BookValuation
9.4x4/10

Trading at 9.4x book value

P/E RatioValuation
59.9x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : AMGN

The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.

Bull Case : ISRG

The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.4% and operating margin at 30.2%. Revenue growth of 18.8% demonstrates continued momentum.

Bear Case : AMGN

The primary concerns for AMGN are PEG Ratio, Price/Book.

Bear Case : ISRG

The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 59.9x leaves little room for execution misses.

Key Dynamics to Monitor

AMGN profiles as a mature stock while ISRG is a growth play — different risk/reward profiles.

ISRG carries more volatility with a beta of 1.68 — expect wider price swings.

ISRG is growing revenue faster at 18.8% — sustainability is the question.

AMGN generates stronger free cash flow (961M), providing more financial flexibility.

Bottom Line

AMGN scores higher overall (70/100 vs 62/100), backed by strong 21.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amgen Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Visit Website →

Intuitive Surgical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Want to dig deeper into these stocks?